The potential for improving cardio-renal outcomes by sodium-glucose co-transporter-2 inhibition in people with chronic kidney disease: a rationale for the EMPA-KIDNEY study

Mostrar otras versiones (1)
Detalles Bibliográficos
Autores principales: Herrington, William G, Preiss, David, Haynes, Richard, von Eynatten, Maximilian, Staplin, Natalie, Hauske, Sibylle J, George, Jyothis T, Green, Jennifer B, Landray, Martin J, Baigent, Colin, Wanner, Christoph
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2019
Materias:
Errata
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7467589/
https://www.ncbi.nlm.nih.gov/pubmed/32905262
http://dx.doi.org/10.1093/ckj/sfz009

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7467589/
https://www.ncbi.nlm.nih.gov/pubmed/32905262
http://dx.doi.org/10.1093/ckj/sfz009

Ejemplares similares